Literature DB >> 15588056

Marburg and Ebola viruses as aerosol threats.

Elizabeth K Leffel1, Douglas S Reed.   

Abstract

Ebola and Marburg viruses are the sole members of the genus Filovirus in the family Filoviridae. There has been considerable media attention and fear generated by outbreaks of filoviruses because they can cause a severe viral hemorrhagic fever (VHF) syndrome that has a rapid onset and high mortality. Although they are not naturally transmitted by aerosol, they are highly infectious as respirable particles under laboratory conditions. For these and other reasons, filoviruses are classified as category A biological weapons. However, there is very little data from animal studies with aerosolized filoviruses. Animal models of filovirus exposure are not well characterized, and there are discrepancies between these models and what has been observed in human outbreaks. Building on published results from aerosol studies, as well as a review of the history, epidemiology, and disease course of naturally occurring outbreaks, we offer an aerobiologist's perspective on the threat posed by aerosolized filoviruses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588056     DOI: 10.1089/bsp.2004.2.186

Source DB:  PubMed          Journal:  Biosecur Bioterror        ISSN: 1538-7135


  33 in total

1.  Evaluation of perceived threat differences posed by filovirus variants.

Authors:  Jens H Kuhn; Lori E Dodd; Victoria Wahl-Jensen; Sheli R Radoshitzky; Sina Bavari; Peter B Jahrling
Journal:  Biosecur Bioterror       Date:  2011-11-09

Review 2.  Persistence of category A select agents in the environment.

Authors:  Ryan Sinclair; Stephanie A Boone; David Greenberg; Paul Keim; Charles P Gerba
Journal:  Appl Environ Microbiol       Date:  2007-12-07       Impact factor: 4.792

3.  Generation and characterization of large-particle aerosols using a center flow tangential aerosol generator with a non-human-primate, head-only aerosol chamber.

Authors:  J Kyle Bohannon; Matthew G Lackemeyer; Jens H Kuhn; Jiro Wada; Laura Bollinger; Peter B Jahrling; Reed F Johnson
Journal:  Inhal Toxicol       Date:  2015-05-13       Impact factor: 2.724

4.  Characterization of the receptor-binding domain of Ebola glycoprotein in viral entry.

Authors:  Jizhen Wang; Balaji Manicassamy; Michael Caffrey; Lijun Rong
Journal:  Virol Sin       Date:  2011-06-12       Impact factor: 4.327

5.  Screening and Identification of Marburg Virus Entry Inhibitors Using Approved Drugs.

Authors:  Li Zhang; Shan Lei; Hui Xie; Qianqian Li; Shuo Liu; Qiang Liu; Weijin Huang; Xinyue Xiao; Youchun Wang
Journal:  Virol Sin       Date:  2019-12-20       Impact factor: 4.327

Review 6.  Antibodies for biodefense.

Authors:  Jeffrey W Froude; Bradley Stiles; Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

7.  Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.

Authors:  William D Pratt; Danher Wang; Donald K Nichols; Min Luo; Jan Woraratanadharm; John M Dye; David H Holman; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2010-02-24

8.  Experimental respiratory Marburg virus haemorrhagic fever infection in the common marmoset (Callithrix jacchus).

Authors:  Sophie J Smither; Michelle Nelson; Lin Eastaugh; Thomas R Laws; Christopher Taylor; Simon A Smith; Francisco J Salguero; Mark S Lever
Journal:  Int J Exp Pathol       Date:  2013-02-27       Impact factor: 1.925

9.  Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.

Authors:  Dana L Swenson; Danher Wang; Min Luo; Kelly L Warfield; Jan Woraratanadharm; David H Holman; John Y Dong; William D Pratt
Journal:  Clin Vaccine Immunol       Date:  2008-01-23

10.  Response to imported case of Marburg hemorrhagic fever, the Netherland.

Authors:  Aura Timen; Marion P G Koopmans; Ann C T M Vossen; Gerard J J van Doornum; Stephan Günther; Franchette van den Berkmortel; Kees M Verduin; Sabine Dittrich; Petra Emmerich; Albert D M E Osterhaus; Jaap T van Dissel; Roel A Coutinho
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.